Market Closed -
Nasdaq
16:00:00 2024-06-27 EDT
|
5-day change
|
1st Jan Change
|
31.48
USD
|
+1.29%
|
|
+9.27%
|
-2.54%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
2,057
|
2,493
|
3,268
|
1,892
|
1,765
|
-
|
-
|
Enterprise Value (EV)
1 |
2,022
|
2,449
|
3,214
|
1,759
|
1,473
|
1,241
|
959
|
P/E ratio
|
-14.6
x
|
73.5
x
|
18.6
x
|
15.2
x
|
14.1
x
|
8.08
x
|
6.15
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
12.9
x
|
8.16
x
|
7.46
x
|
3.25
x
|
2.49
x
|
2.11
x
|
1.8
x
|
EV / Revenue
|
12.7
x
|
8.02
x
|
7.34
x
|
3.02
x
|
2.07
x
|
1.48
x
|
0.98
x
|
EV / EBITDA
|
74.2
x
|
23
x
|
22.4
x
|
8.13
x
|
8.47
x
|
3.68
x
|
2.37
x
|
EV / FCF
|
-677
x
|
24.9
x
|
22.3
x
|
8.03
x
|
11.5
x
|
5.16
x
|
2.82
x
|
FCF Yield
|
-0.15%
|
4.01%
|
4.49%
|
12.5%
|
8.72%
|
19.4%
|
35.5%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
56,889
|
58,472
|
59,318
|
58,572
|
56,792
|
-
|
-
|
Reference price
2 |
36.15
|
42.64
|
55.10
|
32.30
|
31.48
|
31.48
|
31.48
|
Announcement Date
|
21-03-25
|
22-02-28
|
23-02-21
|
24-02-22
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
159.7
|
305.4
|
437.9
|
582
|
710.2
|
836.8
|
981.4
|
EBITDA
1 |
27.26
|
106.4
|
143.6
|
216.4
|
174
|
336.9
|
405
|
EBIT
1 |
16.99
|
87.53
|
120.2
|
192
|
198.2
|
316.5
|
408.2
|
Operating Margin
|
10.63%
|
28.66%
|
27.45%
|
32.99%
|
27.9%
|
37.82%
|
41.6%
|
Earnings before Tax (EBT)
1 |
-36.94
|
37.43
|
104.7
|
173.4
|
163.7
|
303.2
|
397.4
|
Net income
1 |
-63.85
|
34.6
|
181.5
|
128.9
|
136.3
|
236.5
|
302.3
|
Net margin
|
-39.97%
|
11.33%
|
41.44%
|
22.14%
|
19.19%
|
28.26%
|
30.8%
|
EPS
2 |
-2.480
|
0.5800
|
2.970
|
2.130
|
2.226
|
3.897
|
5.118
|
Free Cash Flow
1 |
-2.987
|
98.26
|
144.3
|
219.1
|
128.4
|
240.7
|
340.5
|
FCF margin
|
-1.87%
|
32.17%
|
32.95%
|
37.64%
|
18.08%
|
28.76%
|
34.69%
|
FCF Conversion (EBITDA)
|
-
|
92.38%
|
100.5%
|
101.24%
|
73.79%
|
71.45%
|
84.06%
|
FCF Conversion (Net income)
|
-
|
284.01%
|
79.51%
|
170.02%
|
94.23%
|
101.78%
|
112.64%
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
21-03-25
|
22-02-28
|
23-02-21
|
24-02-22
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
91.21
|
85.31
|
107
|
117.2
|
128.3
|
119.1
|
134.2
|
160.3
|
168.4
|
154.6
|
173.5
|
185.5
|
197.2
|
182.9
|
205.4
|
EBITDA
1 |
-
|
-
|
-
|
-
|
-
|
-
|
52.97
|
-
|
-
|
-
|
64.43
|
75.74
|
86.87
|
79.44
|
-
|
EBIT
1 |
28.63
|
27.56
|
33.12
|
11.9
|
47.61
|
40.42
|
46.9
|
64.51
|
40.2
|
52.03
|
11.92
|
58.49
|
60.59
|
65.01
|
74.31
|
Operating Margin
|
31.39%
|
32.3%
|
30.94%
|
10.15%
|
37.11%
|
33.93%
|
34.95%
|
40.25%
|
23.87%
|
33.65%
|
6.87%
|
31.52%
|
30.72%
|
35.54%
|
36.18%
|
Earnings before Tax (EBT)
1 |
24.48
|
23.38
|
29.23
|
7.967
|
44.1
|
37.78
|
44.1
|
51.83
|
39.69
|
51.78
|
2.025
|
51.21
|
50.39
|
55.75
|
72.31
|
Net income
1 |
22.71
|
21.48
|
23.53
|
87.79
|
48.51
|
29.48
|
34.3
|
38.47
|
26.61
|
38.33
|
1.162
|
38.64
|
38.14
|
42.55
|
55.24
|
Net margin
|
24.9%
|
25.18%
|
21.99%
|
74.91%
|
37.81%
|
24.75%
|
25.56%
|
24%
|
15.8%
|
24.79%
|
0.67%
|
20.83%
|
19.34%
|
23.26%
|
26.9%
|
EPS
2 |
0.3800
|
0.3500
|
0.3900
|
1.440
|
0.7900
|
0.4800
|
0.5600
|
0.6300
|
0.4500
|
0.6700
|
0.0133
|
0.7083
|
0.7200
|
0.6850
|
0.8750
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
22-02-28
|
22-05-03
|
22-08-02
|
22-11-01
|
23-02-21
|
23-05-02
|
23-08-01
|
23-10-31
|
24-02-22
|
24-04-30
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
34.4
|
44.3
|
54.1
|
133
|
292
|
524
|
806
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-2.99
|
98.3
|
144
|
219
|
128
|
241
|
340
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
29.6%
|
37.5%
|
32.1%
|
28.8%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
2 |
-
|
-
|
-
|
3.630
|
3.720
|
4.650
|
-
|
Capex
1 |
0
|
0.3
|
0.17
|
0.31
|
0.97
|
0.41
|
1.59
|
Capex / Sales
|
0%
|
0.1%
|
0.04%
|
0.05%
|
0.14%
|
0.05%
|
0.16%
|
Announcement Date
|
21-03-25
|
22-02-28
|
23-02-21
|
24-02-22
|
-
|
-
|
-
|
Last Close Price
31.48
USD Average target price
43.62
USD Spread / Average Target +38.58% Consensus |
1st Jan change
|
Capi.
|
---|
| -2.54% | 1.79B | | +55.95% | 819B | | +43.62% | 638B | | -6.98% | 351B | | +19.08% | 329B | | +9.05% | 298B | | +16.30% | 242B | | +2.41% | 225B | | +12.47% | 217B | | +8.91% | 168B |
Other Pharmaceuticals
|